View printer-friendly version
« Back
November 15, 1999 10:36 a.m.
Teva Pharmaceutical Industries, Ltd. Responds To Israeli News Articles
Jerusalem, Israel, November 15, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) said today, in response to reports in the Israeli press, that in accordance with the consolidation that is taking place within the global pharmaceutical industry, the Company, as part of its normal course of doing business, is having various discussions with numerous parties in various geographical markets regarding possible cooperations and/or collaboration. One of these companies is Agis Industries Pharmaceuticals, one of Israel's largest pharmaceutical companies. At this time, these discussions are preliminary and have not reached a stage that requires further comment from Teva.

Teva Pharmaceutical Industries Ltd., is Israel's largest pharmaceutical company, with 80% of its sales outside Israel, mainly in the United States and Europe. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, active pharmaceutical ingredients, medical disposables and veterinary products.


Safe Harbor Statement: This release contains-forward looking statements which express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, fluctuations in currency, exchange and interest rates, operating results, the impact of the year 2000 issue and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission.
 
Teva Pharmaceutical Industries Ltd